Intervention

Ritonavir

ClinicalTrials.gov intervention label

Clinical trials135

Recruiting1

Common conditions25

Lead sponsors shown15

Clinical trials

60 shown

A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid TumorsNCT05150691 · 2022-01-31

Investigation of Drug-drug Interaction of Ritonavir and Itraconazole on the Pharmacokinetics of SHR-A1811 in Subjects With HER2-expressing Advanced Breast CancerNCT06710990 · 2025-02-17

A Study of Extending Relugolix Dosing Intervals Through Addition of Itraconazole or Ritonavir in Prostate Cancer PatientsNCT05679388 · 2023-02-13

A Study to Learn About the Medicine Called Nirmatrelvir Used in Combination With Ritonavir in People With Weakened Immune Systems or at Increased Risk for Poor Outcomes Who Are Hospitalized Due to Severe COVID-19NCT05545319 · 2022-12-13

Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and PostpartumNCT04518228 · 2021-09-01

Inflammation and Co-Infections in D²EFTNCT04183738 · 2021-02-01

Nucleosides And Darunavir/Dolutegravir In AfricaNCT03988452 · 2019-07-30

Dolutegravir and Darunavir Evaluation in Adults Failing TherapyNCT03017872 · 2017-11-23

A Drug Interaction Study to Assess the Pharmacokinetics of Narlaprevir and Antiretroviral DrugsNCT03537404 · 2017-04-24

Single and Repeated Dose Escalation Study of GSK2838232NCT02795754 · 2016-03-01

A Drug-drug Interaction Study Between Daclatasvir and Atazanavir/Ritonavir or Atazanavir/CobicistatNCT02565888 · 2015-11-01

Cost-effectiveness of Different Antiretroviral Treatment in Patients HIV NaiveNCT02470650 · 2015-06-01

Safety and Efficacy of Doravirine (MK-1439) in Participants With Human Immunodeficiency Virus 1 (HIV-1) (MK-1439-018)NCT02275780 · 2014-12-01

A Repeat Dose Pharmacokinetic (PK) and Safety Study of GSK2838232 With and Without Ritonavir (RTV) Conducted in Healthy SubjectsNCT02289495 · 2014-11-18

A Single Dose Pharmacokinetic (PK) and Safety Study of GSK2838232 With and Without Ritonavir (RTV) Conducted in Healthy SubjectsNCT02289482 · 2014-11-17

Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)NCT02116660 · 2014-09-03

Study in Healthy Volunteers to Investigate the Safety, Tolerability and Pharmacokinetics of VM-1500NCT02489487 · 2014-09-01

Drug-drug Interaction (DDI) RifabutinNCT02138084 · 2014-05-14

A Study to Determine Safety and Efficacy of Dolutegravir/Abacavir/Lamivudine (DTG/ABC/3TC) in Human Immunodeficiency Virus (HIV)-1 Infected Antiretroviral Therapy (ART) Naïve Women (ARIA)NCT01910402 · 2013-08-22

The Interaction of Two HIV Medications With Blood Clot Medications in Healthy VolunteersNCT01896622 · 2013-06-18

Study to Evaluate a HIV Drug for the Treatment of HIV InfectionNCT01803074 · 2013-04-04

Single Dose Escalation Study of GSK2838232 in Healthy SubjectsNCT01802918 · 2013-02-18

Safety Sudy of Atazanavir Boosted With Ritonavir in the Treatment of HIV Infection in Pediatric PatientsNCT01691794 · 2012-11-30

Open-Label Study Comparing Efficacy and Safety of ATV/RTV+3TC With ATV/RTV+TDF/FTC in HIV-Infected, Treatment Naïve Subjects, Followed by Treatment With ATV/RTV+3TCNCT01620944 · 2012-07-31

Second-line Treatment of HIV-1 With Ritonavir Boosted Atazanavir or Darunavir With an Optimized NRTI BackboneNCT01605084 · 2012-06-30

Pharmacokinetic Study of Pitavastatin and Ritonavir-Boosted Darunavir or EfavirenzNCT01695954 · 2012-05-01

A Clinical Trial Comparing the Efficacy of Darunavir/Ritonavir Monotherapy Versus a Triple Combination Therapy Containing Darunavir/Ritonavir and 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Patients With Undetectable Plasma HIV-1 RNA on Current TreatmentNCT01448707 · 2012-03-15

Part A: Drug Interaction Study of Sofosbuvir and Antiretroviral Therapy (ART) Combinations in HIV and Hepatitis C Virus (HCV) Co-infected Patients. Part B: Efficacy and Safety of Sofosbuvir for 12 Weeks in HIV/HCV Co-infected Patients.NCT01565889 · 2012-03-01

TMC114IFD3001 - Study Providing Continued Access to Treatment With Darunavir (DRV)/Ritonavir(Rtv) in HIV1 Infected Adults, Adolescents and Children Aged 3 Years or Above and Coming From Previous Company Sponsored Studies With DRVNCT01281813 · 2011-08-08

Effect of Multiple Dosing With BI 201335 on the Pharmacokinetics of Darunavir Co-administered With Ritonavir in Healthy Male and Female VolunteersNCT01374802 · 2011-06-01

Phase IIIB Study Evaluating the Effects of Atazanavir Powder With Ritonavir in HIV-infected Pediatric PatientsNCT01335698 · 2011-05-27

Effects of Famotidine on the Pharmacokinetics of Atazanavir When Coadministered to Participants With HIV InfectionNCT01232127 · 2011-02-01

Drug Interaction Between Ritonavir And SitaxsentanNCT01251848 · 2011-01-01

GSK1349572 Drug Interaction Study With Fosamprenavir/RitonavirNCT01209065 · 2010-09-01

The Influence of Ritonavir, Alone and in Combination With Lopinavir, on Fenofibric Acid Pharmacokinetics in Healthy VolunteersNCT01148004 · 2010-05-13

A Study of the Once Daily Combination of Etravirine and Darunavir/Ritonavir As Dual Therapy in Early Treatment-Experienced PatientsNCT01199939 · 2010-05-01

Tenofovir, Emtricitabine, Efavirenz and Atazanavir Pharmacokinetics in the Aging HIV-Infected PopulationNCT01180075 · 2010-05-01

Study to Evaluate the Safety and Efficacy of Stribild Versus Ritonavir-Boosted Atazanavir Plus Truvada in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive AdultsNCT01106586 · 2010-04-01

Pharmacodynamics, Safety and Pharmacokinetics of BMS-663068, an HIV Attachment Inhibitor, in HIV-1NCT01009814 · 2009-11-23

Drug Interactions Between Voriconazole and Atazanavir Coadministered as Atazanavir/Ritonavir in Healthy ParticipantsNCT00833482 · 2009-09-01

A Safety Study to Evaluate the Antiviral Activity of Darunavir in Combination With Ritonavir in HIV 1 Infected ChildrenNCT00919854 · 2009-09-01

Drug Interaction Study Between Inhaled Beclomethasone and Protease Inhibitors in Healthy VolunteersNCT00936793 · 2009-07-06

Study in Healthy Males to Measure Darunavir and Etravirine in Blood, Seminal Fluid, and Rectal TissueNCT00855088 · 2009-07-01

A Study to Compare Brachial Artery Reactivity and Cardiovascular Risk of a Treatment Simplification by Darunavir/Ritonavir (DRV/r) 800/100 mg Versus a Triple Combination Therapy Containing DRV/r in HIV-1 Infected PatientsNCT01391013 · 2009-06-01

Impact of Antiretroviral Therapy on Metabolic, Skeletal, and Cardiovascular ParametersNCT00851799 · 2009-06-01

Comparative Study of Three NNRTI-Sparing HAART RegimensNCT00811954 · 2009-05-01

A Single-arm, Open-label, Study to Assess the Pharmacokinetics of Darunavir and Ritonavir, Darunavir and Cobicistat, Etravirine, and Rilpivirine in HIV-1 Infected Pregnant WomenNCT00855335 · 2009-04-09

HIV Viremia and Persistence in Acutely HIV-Infected Patients Treated With Darunavir/Ritonavir and EtravirineNCT00855413 · 2009-03-01

Pharmacokinetic Study of Posaconazole Boosted FosamprenavirNCT00817765 · 2009-01-01

Raltegravir And Darunavir Antiretroviral in Antiretroviral Naive PatientsNCT00677300 · 2009-01-01

Phase IIB Pilot of Atazanavir + RaltegravirNCT00768989 · 2008-11-01

Pharmacokinetics, Safety And Toleration Of Maraviroc Administered To Subjects With Various Degrees Of Renal Impaired And Normal Renal FunctionNCT00717067 · 2008-07-01

Genetic Predictors of Variability in the Drug-drug Interaction Between Darunavir/Ritonavir and PravastatinNCT00630734 · 2008-02-01

Measure of Pharmacokinetic Parameters and Adherence With MEMS in Naive HIV Infected Patients Treated With Reyataz Once Daily Combined With Norvir and TruvadaNCT00528060 · 2008-01-01

Comparison of TPV/r to DRV/r in Triple Class Experienced Patient With Resistance to > 1 PINCT00517192 · 2007-09-01

A Study of Saquinavir/Ritonavir in Liver-Impaired Patients With HIV Infection.NCT00435929 · 2006-09-01

Observational Non-interventional Study (Anwendungsbeobachtung) With Aptivus® (Tipranavir) in HIV-infected Patients.NCT00531206 · 2006-08-01

A Phase 2 Study to Evaluate Pharmacokinetics, Safety and Efficacy of TMC114/Ritonavir (Rtv) in Human Immunodeficiency Virus (HIV)-1 Infected Children and AdolescentsNCT00355524 · 2006-06-01

Blood Levels of Anti-HIV Drugs Used in Combination Regimens in HIV Infected ChildrenNCT00260078 · 2006-02-01

Pharmacokinetics (PK) of Tipranavir/Ritonavir, Ribavirin, Pegylated Interferon (Peg INF) in Hepatitis C (HCV) Subjects With Mild Hepatic Impairment and in HCV, Hepatitis B (HBV), Hepatitis D Infected Subjects or Alcoholic Cirrhosis With Moderate Hepatic ImpairmentNCT02259855 · 2006-01-01

Common conditions

Leading sponsors

National Institute of Allergy and Infectious Diseases (NIAID)42 Bristol-Myers Squibb8 Hoffmann-La Roche8 ViiV Healthcare8 Boehringer Ingelheim7 GlaxoSmithKline6 Merck Sharp & Dohme LLC6 Abbott4 Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections3 French National Agency for Research on AIDS and Viral Hepatitis3 Gilead Sciences3 Glaxo Wellcome3 Kirby Institute3 National Institutes of Health Clinical Center (CC)3 University of North Carolina, Chapel Hill3

Trial status mix

COMPLETED104

TERMINATED12

UNKNOWN10

WITHDRAWN7

APPROVED_FOR_MARKETING1

RECRUITING1

Phase mix

PHASE140

PHASE239

PHASE325

NA18

PHASE412

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.